A Guide to Understanding New Synthetic Psychoactive Substances (NPS)

New Synthetic Opioids: A Growing Concern

In the shadows of the internet, a new breed of powerful psychoactive substances is readily available, cheap, and pure. These synthetic opioids, such as fentanyl” title=”New Opioids Called Nitazenes May Be 20 Times Stronger Than Fentanyl”>nitazènes and fentanyl, are causing a stir in the headlines, but what does science have to say about them?

Synthetic Novel Psychoactive Substances (NPS) are substances that mimic the effects of illicit drugs like ecstasy, amphetamines, cocaine, cannabis, and opioids. Their varied compositions lead to a wide range of physical, psychiatric, and cognitive complications. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has identified 930 NPS, with 41 new ones in 2022 alone.

In France, the French Observatory for Drugs and Drug Addiction (OFDT) has recorded 368 NPS since 2008, with 35 new ones in 2021. These include stimulants like cathinones, synthetic cannabinoids, and hallucinogens like phenethylamines. A task force led by Professor Laurent Karila and the Interministerial Mission for the Fight against Drugs and Addictive Behaviors (MILDECA) has developed a brochure for professionals, identifying different categories of NPS. They also created a free Android and iOS app called NPS PSYCHOACTIFS.

New Synthetic Opioids: Identification and Management

Producers constantly modify the molecular structures of NPS to evade drug legislation, making it challenging for the legal framework to keep up. While some first-generation cathinone derivatives have been classified as narcotics, newer families and individual substances are continually emerging.

The increasing use of NPS in festive settings and chemsex (sex combined with psychoactive substance use) is leading to more severe intoxications and deaths. Between 2009 and 2017, 800 serious cases were reported in France, with 9% resulting in fatalities. The growing online market for psychoactive substances underscores the urgency to monitor the availability and health risks of NPS.

In emergency and intensive care units, a specific protocol is in place to manage NPS-related cases. Liaison and care teams in addiction (ELSA) and centers for evaluation and information on pharmacodependence-addictovigilance (CEIP-A) play crucial roles in specialized care and analyzing clinical complications.

New Synthetic Opioids: A Growing Concern

New synthetic opioids, initially developed for therapeutic purposes, are now produced in clandestine labs. These potent psychoactive substances are easily accessible online, affordable, and highly pure. They cannot be detected in routine toxicology tests, posing significant health risks.

New synthetic opioids (NOS) come in various forms (powder, pills) and are consumed orally, intranasally, or intravenously. They have rapid onset and short duration, acting as depressants. Overdose symptoms include respiratory depression, cyanosis, myosis, somnolence, altered consciousness, bradycardia, nausea, anxiety, and abdominal pain.

Naloxone: An Antidote

Naloxone, an opioid receptor antagonist, is used to reverse NOS overdoses. However, higher doses and repeated administrations may be necessary compared to heroin or morphine overdoses. Between 2013 and 2019, US opioid-related deaths increased by 1,040%. In 2021, EU countries reported around 140 fentanyl-related deaths. In France, several deaths have been reported, including those involving nitazènes.

Legal Framework

Several synthetic opioids, including 3-fluorofentanyl, 4-fluorobutyr(yl)fentanyl, and isotonitazène, are classified as narcotics. The legal framework aims to control these substances, but the constant evolution of NPS structures poses challenges. Healthcare professionals and the public must stay informed and vigilant about these emerging threats.

As the availability and use of new synthetic opioids continue to grow, so does the need for education, vigilance, and accessible treatment options. By understanding these substances and their risks, we can work towards mitigating their harmful effects.

Battling a Moving Target: Confronting the Ever-Evolving Threat of ⁢Synthetic Opioids

The world ⁢of synthetic ⁢opioids ⁤represents a formidable challenge. Thier alarming potency, accessibility, and unrelenting evolution demand a multifaceted approach to combat their devastating impact.

While pharmaceutical companies search for medicinal applications of opioid ⁢analogs, the illicit market⁤ weaponizes ‍these same compounds, producing designer drugs that are deadly and difficult ‍to regulate. The continuous modifications to their chemical structures outpace legal responses, creating a perilous game of catch-up for law enforcement and health professionals.

The ⁤ French⁢ initiative‍ led by Professor Karila and MILDECA, with its online resources and public awareness campaigns, provides a vital example of proactive engagement. ⁢Similarly, international collaboration is crucial, sharing intelligence on new compounds, refining analysis techniques, and adapting treatment ⁤protocols to address the evolving nature of this threat.

Ultimately, prevention and education remain paramount. By ⁢deepening public understanding of the risks ⁣associated with synthetic opioids and promoting harm reduction strategies, we can empower‍ individuals to make⁤ informed choices and minimize the tragic consequences of this insidious ⁤drug epidemic. The battle against synthetic ⁤opioids is ongoing, but by staying⁣ informed, sharing knowledge, and ⁣working together, we can hope to protect ⁢vulnerable populations and safeguard ⁣public health.

The Urgent Need for Vigilance and Action

The proliferation of new synthetic opioids, their potent effects, and their readily available nature online pose a serious and escalating threat to public health.

As demonstrated, these substances present unique challenges, evading traditional detection methods, mimicking the effects of known opioids, and necessitating specialized treatment protocols. While naloxone provides a crucial tool for reversing overdose, its efficacy varies, emphasizing the need for ongoing research into more effective countermeasures.

The rise of NPS highlights the urgent need for a multi-pronged approach:

Strengthening Legislation: Continuous adaptation of legal frameworks is crucial to keep pace with rapidly evolving synthetic compounds.

Increased Awareness: Complete public education campaigns are vital to inform individuals about the dangers of these substances and promote harm reduction strategies.

Enhanced Surveillance and Monitoring: Continuously monitoring the emergence of new NPS, understanding their prevalence, and identifying emerging trends is critical for effective prevention and intervention.

Improved Access to Treatment: Expanding access to specialized addiction treatment, including pharmacological interventions and behavioral therapies, is essential for those struggling with NPS use.

* International Collaboration: Given the global nature of this issue, coordinated international efforts are paramount to share facts, develop strategies, and combat the production and trafficking of these hazardous substances.

The fight against new synthetic opioids requires a sustained commitment from policymakers, healthcare providers, researchers, and the public. Onyl through collective action can we mitigate the devastating consequences of this growing public health crisis.